July 2, 2024
Headlines

Healthtech

Ethris GmbH: Leading the Charge in mRNA-Based Therapeutics with $5 Million Investment

Editor04 mins

Since its inception, Ethris GmbH has been a trailblazer in mRNA technology, revolutionizing the biotech landscape with its innovative approach to respiratory and cardiovascular diseases. Founded on a vision of harnessing messenger RNA (mRNA) for therapeutic breakthroughs, Ethris has consistently pushed boundaries, drawing attention from investors and global biotech leaders alike. Breakthroughs and Strategic Growth…

Read More

PolTREG Reports Long-Term Success in Type-1 Diabetes Treatment Study

Editor03 mins

PolTREG S.A., a pioneering biotechnology firm specializing in cellular therapies for autoimmune disorders, has announced groundbreaking findings from its long-term clinical study on PTG-007, a polyclonal Treg cell therapy for early-onset type-1 diabetes (T1D). Over a span of 7 to 12 years, pediatric patients treated with PTG-007 demonstrated sustained insulin secretion, contrasting starkly with a…

Read More

Marea Therapeutics Secures $190 Million to Propel Novel Cardiovascular Treatments

Editor04 mins

Marea Therapeutics has marked a significant milestone with the successful closure of a $190 million combined Series A and B financing, positioning the clinical-stage biotechnology firm to accelerate its pioneering efforts in cardiometabolic disease treatments. Led by Third Rock Ventures and supported by a consortium of leading investors including Sofinnova Investments, Forbion, and Perceptive Xontogeny…

Read More